Rigo-Adrover M, Saldaña-Ruíz S, van Limpt K, Knipping K, Garssen J, Knol J, Franch A, Castell M, Pérez-Cano F J
Department of Physiology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Nutrition and Food Safety Research Institute (INSA), Barcelona, Spain.
Eur J Nutr. 2017 Jun;56(4):1657-1670. doi: 10.1007/s00394-016-1213-1. Epub 2016 Apr 25.
Rotavirus (RV) is the leading cause of severe diarrhoea among infants and young children, and although more standardized studies are needed, there is evidence that probiotics can help to fight against RV and other infectious and intestinal pathologies. On the other hand, the effects of prebiotics have not been properly addressed in the context of an RV infection. The aim of this study was to demonstrate a protective role for a specific scGOS/lcFOS 9:1 prebiotic mixture (PRE) separately, the probiotic Bifidobacterium breve M-16V (PRO) separately and the combination of the prebiotic mixture and the probiotic (synbiotic, SYN) in a suckling rat RV infection model.
The animals received the intervention from the 3rd to the 21st day of life by oral gavage. On day 7, RV was orally administered. Clinical parameters and immune response were evaluated.
The intervention with the PRO reduced the incidence, severity and duration of the diarrhoea (p < 0.05). The PRE and SYN products improved clinical parameters as well, but a change in stool consistency induced by the PRE intervention hindered the observation of this effect. Both the PRE and the SYN, but not the PRO, significantly reduced viral shedding. All interventions modulated the specific antibody response in serum and intestinal washes at day 14 and 21 of life.
A daily supplement of a scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V or a combination of both is highly effective in modulating RV-induced diarrhoea in this preclinical model.
轮状病毒（RV）是婴幼儿严重腹泻的主要病因，尽管需要更多标准化研究，但有证据表明益生菌有助于对抗RV及其他传染性和肠道疾病。另一方面，在RV感染的背景下，益生元的作用尚未得到充分研究。本研究的目的是在乳鼠RV感染模型中，分别证明特定的scGOS/lcFOS 9:1益生元混合物（PRE）、益生菌短双歧杆菌M-16V（PRO）以及益生元混合物与益生菌的组合（合生元，SYN）的保护作用。
动物在出生后第3天至第21天通过口服灌胃接受干预。在第7天，口服给予RV。评估临床参数和免疫反应。
PRO干预降低了腹泻的发生率、严重程度和持续时间（p < 0.05）。PRE和SYN产品也改善了临床参数，但PRE干预引起的粪便稠度变化妨碍了对这一效果的观察。PRE和SYN均显著降低了病毒排泄，但PRO未降低。所有干预均在出生后第14天和第21天调节了血清和肠道灌洗液中的特异性抗体反应。
在这个临床前模型中，每日补充scGOS/lcFOS 9:1益生元混合物、短双歧杆菌M-16V或两者的组合在调节RV诱导的腹泻方面非常有效。
